Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease
Molecular and Cellular Endocrinology · 2024-03 · 582 · 112139
DOI: 10.1016/j.mce.2023.112139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2024-03. Verfasst von Tian Gan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Experimental, Ferroptosis. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Impaired fatty acid oxidation (FAO) is a metabolic hallmark of renal tubular epithelial cells (RTECs) under diabetic conditions. Disturbed FAO may promote cellular oxidative stress and insufficient energy production, leading to ferroptosis subsequently. Canagliflozin, an effective anti-hyperglycemic drug, may exert potential reno-protective effects by upregulating FAO and inhibiting ferroptosis in RTECs. However, the mechanisms involved remain unclear. The present study is aimed to characterize the detailed mechanisms underlying the impact of canagliflozin on FAO and ferroptosis. Type 2 diabetic db/db mice were administrated daily by gavage with canagliflozin (20 mg/kg/day, 40 mg/kg/day) or positive control drug pioglitazone (10 mg/kg/day) for 12 weeks. The results showed canagliflozin effectively improved renal function and structure, reduced lipid droplet accumulation, enhanced FAO with increased ATP contents and CPT1A expression, a rate-limiting enzyme of FAO, and relieved ferroptosis in diabetic mice. Moreover, overexpression of FOXA1, a transcription factor related with lipid metabolism, was observed to upregulate the level of CPT1A, and further alleviated ferroptosis in high glucose cultured HK-2 cells. Whereas FOXA1 knockdown had the opposite effect. Mechanistically, chromatin immunoprecipitation assay and dual-luciferase reporter gene assay results demonstrated that FOXA1 transcriptionally promoted the expression of CPT1A through a sis-inducible element located in the promoter region of the protein. In conclusion, these data suggest that canagliflozin improves FAO and attenuates ferroptosis of RTECs via FOXA1-CPT1A axis in diabetic kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
- Department of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
- Department of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Electronic address: hyqingj@zzu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Gan, T., Wang, Q., Song, Y., Shao, M., Zhao, Y., Guo, F., Wei, F., Fan, X., Zhang, W., Luo, Y., Chen, D., Wang, S., & Qin, G. (2024). Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease. Molecular and Cellular Endocrinology, 582, 112139. https://doi.org/10.1016/j.mce.2023.112139
Vancouver
Gan T, Wang Q, Song Y, Shao M, Zhao Y, Guo F, et al. Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease. Molecular and Cellular Endocrinology. 2024;582:112139. doi:10.1016/j.mce.2023.112139
BibTeX
@article{Gan2024,
author = {Gan, Tian and Wang, Qingzhu and Song, Yi and Shao, Mingwei and Zhao, Yanyan and Guo, Feng and Wei, Fangyi and Fan, Xunjie and Zhang, Wei and Luo, Yuanyuan and Chen, Duo and Wang, Shanshan and Qin, Guijun},
title = {Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease},
journal = {Molecular and Cellular Endocrinology},
year = {2024},
volume = {582},
pages = {112139},
doi = {10.1016/j.mce.2023.112139}
}
EUVIMED